Kissei gains exclusive rights to develop and commercialize olutasidenib in all current and potential indications in Japan, the Republic of Korea and Taiwan Rigel will receive an upfront cash payment of $10.0 million with the potential for up to $152.5 million in future development, regulatory, and commercial milestone payments Rigel to receive product transfer price payments in the mid-twenty to lower-thirty percent range based on tiered net sales for exclusive supply of REZLIDHIA SOUTH SAN FRANCISCO, Calif ...

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference, Boston, MA Mr. Schorno will participate in one-on-one meetings on Thursday, September 5th. H.C. Wainwright 26th Annual Global Investment Con ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Ray Furey - EVP, General Counsel and Corporate Secretary Raul Rodriguez - President and CEO Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - CFO Conference Call Participants Yigal Nochomovitz - Citi Kristen Kluska - Cantor Joe Pantginis - H.C. Wainwright Operator Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the S ...

Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 83.78%. A quarter ago, it was expected that this drug developer would post a loss of $0.30 per share when it actually produced a loss of $0.50, delivering a surprise of -66.67%. Over the last four quarters, the comp ...

Exhibit 99.1 Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update · Second quarter total revenue of $36.8 million, which includes TAVALISSE net product sales of $26.4 million, REZLIDHIA net product sales of $5.2 million and GAVRETOnet product sales of $1.9 million · Successfully completed NDA transfer of GAVRETO for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer, with product available from Rigel beginning June ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (Sta ...

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website. Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing n ...

Source : Mordor Intelligence Product Pipeline: Progress and Updates ■ TAVALISSE PHASE 1 Lower-Risk Myelodysplastic Syndrome Target: Interleukin receptor-associated kinases 1 and 4 (IRAK1/4) NSCLC Target: AXL receptor tyrosine kinase (AXL) Milademetan' - Daiichi Sankyo CNS Diseases Target: RIPK1 PRE-CLINICAL PRE-CL In 2023, Gavreto generated around $28 million in revenues from the US alone. Its action mechanism inhibits RET kinase activity by binding to it, blocking signaling pathways essential for cancer ce ...

SOUTH SAN FRANCISCO, Calif., July 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 79,890 stock options to eleven non-executive employees vesting over four years with ...

The Reverse Stock Split was approved by the company's stockholders at its Annual Meeting of Stockholders held on May 24, 2024 to be effected by the company's Board of Directors (the "Board") within approved parameters. The final ratio was approved by the Board on June 15, 2024. As a result of the Reverse Stock Split, every 10 shares of the company's pre-split common stock issued and outstanding will be automatically reclassified into one new share of the company's common stock. This will reduce the number o ...